Literature DB >> 33844574

Pulmonary Hypertension.

David Poch1, Jess Mandel1.   

Abstract

Pulmonary hypertension is the term used to describe a group of disorders characterized by abnormally high pressures in the pulmonary arteries. Initial evaluation is focused on identifying the cause, which helps guide appropriate treatment. Pulmonary hypertension is often a feature of advanced common diseases, such as chronic obstructive pulmonary disease and left heart disease, and treatment is focused primarily on the underlying disease. More rarely, pulmonary hypertension results from chronic organized thromboemboli or a primary vasculopathy. The former requires evaluation for surgical intervention, and the latter is treated with advanced medical therapies.

Entities:  

Year:  2021        PMID: 33844574     DOI: 10.7326/AITC202104200

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  11 in total

1.  The clinical characteristics and outcomes of patients with pulmonary hypertension in association with hyperthyroid state: A systematic review.

Authors:  Fateen Ata; Adeel Ahmad Khan; Zohaib Yousaf; Hassan Choudry; Areej Marwan Mohammed; Bilal Ahmed; Ahmed Muaaz Umer; Fareeha Khan; Dabia Hamad Sh Al Mohanadi; Emad Naem; Muhammad Zahid
Journal:  Medicine (Baltimore)       Date:  2022-07-01       Impact factor: 1.817

2.  Puerarin-V prevents the progression of hypoxia- and monocrotaline-induced pulmonary hypertension in rodent models.

Authors:  Di Chen; Hui-Fang Zhang; Tian-Yi Yuan; Shu-Chan Sun; Ran-Ran Wang; Shou-Bao Wang; Lian-Hua Fang; Yang Lyu; Guan-Hua Du
Journal:  Acta Pharmacol Sin       Date:  2022-02-21       Impact factor: 7.169

Review 3.  Advances in the Study of Inhaled Formulations for the Treatment of Pulmonary Arterial Hypertension.

Authors:  Fei Han; Yongqi Chen; Shijie Li; Yankun Yang; Zhonghu Bai
Journal:  Appl Bionics Biomech       Date:  2022-06-02       Impact factor: 1.664

4.  The Long-Term Effect of COVID-19 Disease Severity on Risk of Diabetes Incidence and the Near 1-Year Follow-Up Outcomes among Postdischarge Patients in Wuhan.

Authors:  Jun Zhang; Tingting Shu; Rui Zhu; Fengwen Yang; Boli Zhang; Xuefeng Lai
Journal:  J Clin Med       Date:  2022-05-30       Impact factor: 4.964

Review 5.  Target Nuclear Factor Erythroid 2-Related Factor 2 in Pulmonary Hypertension: Molecular Insight into Application.

Authors:  Yuhan Qin; Yong Qiao; Dong Wang; Linqing Li; Mingkang Li; Gaoliang Yan; Chengchun Tang
Journal:  Oxid Med Cell Longev       Date:  2022-06-06       Impact factor: 7.310

6.  Soluble Guanylate Cyclase Stimulators (Riociguat) in Pulmonary Hypertension: Data from Real-Life Clinical Practice in a 3-Year Follow-Up.

Authors:  Fernanda Brum Spilimbergo; Taís Silveira Assmann; Marcelo Bellon; Laís Machado Hoscheidt; Cássia Ferreira Braz Caurio; Márcia Puchalski; Bruno Hochhegger; Gabriela Roncato; Gisela Martina Bohns Meyer
Journal:  Arq Bras Cardiol       Date:  2022-05-09       Impact factor: 2.667

Review 7.  The Role of Gut and Airway Microbiota in Pulmonary Arterial Hypertension.

Authors:  Linlin Huang; Hongdie Zhang; Yijun Liu; Yang Long
Journal:  Front Microbiol       Date:  2022-07-13       Impact factor: 6.064

8.  DNA-PKcs participated in hypoxic pulmonary hypertension.

Authors:  Ying-Ying Liu; Wei-Yun Zhang; Meng-Lan Zhang; Yu-Ji Wang; Xi-Yan Ma; Jung-Hong Jiang; Ran Wang; Da-Xiong Zeng
Journal:  Respir Res       Date:  2022-09-16

9.  Evaluating the therapeutic role of selected active compounds in Plumula Nelumbinis on pulmonary hypertension via network pharmacology and experimental analysis.

Authors:  Xinghua Xiao; Fangmei Luo; Minyi Fu; Yueping Jiang; Shao Liu; Bin Liu
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

Review 10.  Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate (EGCG): A Time for a New Player in the Treatment of Respiratory Diseases?

Authors:  Daniela Mokra; Jana Adamcakova; Juraj Mokry
Journal:  Antioxidants (Basel)       Date:  2022-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.